Hikma launches Ropivacaine HCl Injection, USP for anaesthesia and acute pain management

IndustryPRwire -- Hikma Pharmaceuticals has launched Ropivacaine HCl Injection, USP 40mg/20mL in the US, through its US affiliate, Hikma Pharmaceuticals USA Inc.

Ropivacaine HCl Injection, USP is indicated for the production of local or regional anesthesia for surgery and for acute pain management.  For surgical anesthesia it is used as part of the epidural during caesarean section, to induce major nerve block or is used in local infiltration.  In acute pain management, it is used as part of continuous epidural infusion or can be provided intermittently, for example during postoperative or labor or local infiltration. 

According to IQVIA, US sales of Ropivacaine HCl Injection, USP 40mg/20mL were approximately $4 million in the 12 months ending September 2020.

Hikma is the third largest US supplier of generic injectable medicines by volume, with a growing portfolio of over 100 products.

Related Posts

Subscribe Our Newsletter